Cargando…
Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer
Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse can...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624612/ https://www.ncbi.nlm.nih.gov/pubmed/37488375 http://dx.doi.org/10.1038/s41557-023-01280-4 |
_version_ | 1785130952146550784 |
---|---|
author | Szijj, Peter A. Gray, Melissa A. Ribi, Mikaela K. Bahou, Calise Nogueira, João C. F. Bertozzi, Carolyn R. Chudasama, Vijay |
author_facet | Szijj, Peter A. Gray, Melissa A. Ribi, Mikaela K. Bahou, Calise Nogueira, João C. F. Bertozzi, Carolyn R. Chudasama, Vijay |
author_sort | Szijj, Peter A. |
collection | PubMed |
description | Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse cancer-cell immune-dampening strategies, improving efficacy. So far, protein engineering has been the main approach to generate bsAbs and CiTEs, but improved chemical methods for their generation have recently been developed. Homogeneous fragment-based bsAbs constructed from fragment antigen-binding regions (Fabs) can be generated using click chemistry. Here we describe a chemical method to generate biotin-functionalized three-protein conjugates, which include two CiTE molecules, one containing an anti-PD-1 Fab and the other containing an immunomodulatory enzyme, Salmonella typhimurium sialidase. The CiTEs’ efficacy was shown to be superior to that of the simpler BiTE scaffold, with the sialidase-containing CiTE inducing substantially enhanced T cell-mediated cytotoxicity in vitro. The chemical method described here, more generally, enables the generation of multi-protein constructs with further biological applications. [Image: see text] |
format | Online Article Text |
id | pubmed-10624612 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-106246122023-11-05 Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer Szijj, Peter A. Gray, Melissa A. Ribi, Mikaela K. Bahou, Calise Nogueira, João C. F. Bertozzi, Carolyn R. Chudasama, Vijay Nat Chem Article Bispecific T cell engagers (BiTEs), a subset of bispecific antibodies (bsAbs), can promote a targeted cancer cell’s death by bringing it close to a cytotoxic T cell. Checkpoint inhibitory T cell engagers (CiTEs) comprise a BiTE core with an added immunomodulatory protein, which serves to reverse cancer-cell immune-dampening strategies, improving efficacy. So far, protein engineering has been the main approach to generate bsAbs and CiTEs, but improved chemical methods for their generation have recently been developed. Homogeneous fragment-based bsAbs constructed from fragment antigen-binding regions (Fabs) can be generated using click chemistry. Here we describe a chemical method to generate biotin-functionalized three-protein conjugates, which include two CiTE molecules, one containing an anti-PD-1 Fab and the other containing an immunomodulatory enzyme, Salmonella typhimurium sialidase. The CiTEs’ efficacy was shown to be superior to that of the simpler BiTE scaffold, with the sialidase-containing CiTE inducing substantially enhanced T cell-mediated cytotoxicity in vitro. The chemical method described here, more generally, enables the generation of multi-protein constructs with further biological applications. [Image: see text] Nature Publishing Group UK 2023-07-24 2023 /pmc/articles/PMC10624612/ /pubmed/37488375 http://dx.doi.org/10.1038/s41557-023-01280-4 Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Article Szijj, Peter A. Gray, Melissa A. Ribi, Mikaela K. Bahou, Calise Nogueira, João C. F. Bertozzi, Carolyn R. Chudasama, Vijay Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title | Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title_full | Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title_fullStr | Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title_full_unstemmed | Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title_short | Chemical generation of checkpoint inhibitory T cell engagers for the treatment of cancer |
title_sort | chemical generation of checkpoint inhibitory t cell engagers for the treatment of cancer |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10624612/ https://www.ncbi.nlm.nih.gov/pubmed/37488375 http://dx.doi.org/10.1038/s41557-023-01280-4 |
work_keys_str_mv | AT szijjpetera chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT graymelissaa chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT ribimikaelak chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT bahoucalise chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT nogueirajoaocf chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT bertozzicarolynr chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer AT chudasamavijay chemicalgenerationofcheckpointinhibitorytcellengagersforthetreatmentofcancer |